Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Lucid Diagnostics (LUCD) Shares Outstanding (2020 - 2026)

Lucid Diagnostics filings provide 6 years of Shares Outstanding readings, the most recent being $131.1 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 107.86% to $131.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.1 million, a 107.86% increase, with the full-year FY2025 number at $131.1 million, up 107.86% from a year prior.
  • Shares Outstanding hit $131.1 million in Q4 2025 for Lucid Diagnostics, roughly flat from $130.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $131.1 million in Q4 2025 to a low of $13625.0 in Q1 2023.
  • Median Shares Outstanding over the past 5 years was $36.5 million (2022), compared with a mean of $38.7 million.
  • Biggest five-year swings in Shares Outstanding: crashed 99.89% in 2024 and later surged 190426.04% in 2025.
  • Lucid Diagnostics' Shares Outstanding stood at $34.9 million in 2021, then grew by 16.04% to $40.5 million in 2022, then rose by 4.47% to $42.3 million in 2023, then skyrocketed by 49.0% to $63.1 million in 2024, then soared by 107.86% to $131.1 million in 2025.
  • The last three reported values for Shares Outstanding were $131.1 million (Q4 2025), $137.5 million (Q3 2025), and $101.8 million (Q2 2025) per Business Quant data.